LLS News Network

News and Information from The Leukemia & Lymphoma Society

CANCER IS TOUGH, BUT LLS IS TOUGHER

View full release here.  Rye Brook, NY (August 28, 2018) – Contributing to nearly every advance in blood cancer research and treatment in decades, The Leukemia & Lymphoma Society (LLS) has invested more than $1.2 billion in cancer research, with groundbreaking results in immunotherapy, genomics and personalized medicine that are improving and saving lives of patients. These revolutionary new t...

LLS Renews Call for Strong Action to Ease the Soaring Cost of Ca...

View multimedia release here. Rye Brook, N.Y. (Aug. 7, 2018) — As costs for cancer care skyrocket – projected to be $173 billion by 2020, a 39 percent increase from 2010 – The Leukemia & Lymphoma Society® (LLS) is renewing its call for action to ease the cost of cancer care for patients. Today, LLS released a national “Progress Report on the Cost of Cancer Care,” a review of policy measures tak...

FDA Approval of New Precision Medicine Therapy for Deadly Blood C...

Rye Brook, N.Y. (July 20, 2018) – Progress in treating acute myeloid leukemia (AML), a blood cancer that takes more than 10,000 lives in the United States each year, took an important step forward today with the U.S. Food & Drug Administration (FDA) approval of ivosidenib (Tibsovo®) for patients who have a specific genetic mutation called IDH1. The Leukemia & Lymphoma Society (LLS), a leader i...

LLS Announces Board of Directors Appointments and New Chief Opera...

(Rye Brook, NY, July 10, 2018) - The Leukemia & Lymphoma Society (LLS) announced today five new appointments to its board of directors, including four influential research scientists; Casey Cunningham, M.D., Christopher Flowers, M.D., Janice L. Gabrilove, M.D. and Ruben A. Mesa, M.D. Their appointments build strength in the diagnosis and treatment of lymphoma and myeloproliferative neoplasms as well as methods fo...

Media Contact

Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday: